Publish in this journal
Journal Information
Vol. 70. Issue 2.
Pages 121-122 (February 2017)
Download PDF
More article options
Vol. 70. Issue 2.
Pages 121-122 (February 2017)
Scientific letter
DOI: 10.1016/j.rec.2016.06.018
Full text access
Concomitant Rivaroxaban and Dronedarone Administration in Patients With Nonvalvular Atrial Fibrillation
Administración simultánea de rivaroxabán y dronedarona en pacientes con fibrilación auricular no valvular
Carlos Escobara, Martín Arceluza, Rosa Montes de Ocaa, Ricardo Moria, José Luis López-Sendónb, José Luis Merinoa,
Corresponding author
a Servicio de Cardiología, Hospital Universitario La Paz, IdiPaz, Madrid, Spain
b Unidad de Electrofisiología Robotizada, Hospital Universitario La Paz, IdiPaz, Madrid, Spain
This item has received
(Daily data update)
Article information
Full Text
Download PDF
Tables (1)
Table. Baseline Characteristics and Clinical Events in Patients With Nonvalvular Atrial Fibrillation Treated With Rivaroxaban and Dronedarone
Full Text
To the Editor,

Direct oral anticoagulants have a wide therapeutic window, a predictable anticoagulant effect, and low risk of drug-drug interactions. They are at least as effective as warfarin for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) but have a better safety profile, particularly with regard to the risk of intracranial hemorrhage.1

Dronedarone is an antiarrhythmic agent currently indicated for the maintenance of sinus rhythm after successful cardioversion in clinically stable adults with paroxysmal or persistent AF.2 Remarkably, dronedarone significantly reduces the risk of AF recurrence and the incidence of hospitalization due to cardiovascular events or death in patients with paroxysmal or persistent AF.3,4 However, concomitant treatment with dabigatran and dronedarone is contraindicated, since the area under the curve of dabigatran increases by more than 100% with the addition of dronedarone. However, data on the safety of the coadministration of rivaroxaban with dronedarone is lacking and, for this reason, there is no specific recommendation on this issue in the current EHRA Practical Guide on the use of direct oral anticoagulants in NVAF. In fact, in the EHRA guideline, concomitant rivaroxaban and dronedarone use is marked as a “yellow” interaction, with the recommendation to maintain the original dose, unless 2 or more concomitant ‘yellow’ interactions are present.5 The aim of this study was to determine whether there are significant clinical consequences of combining rivaroxaban with dronedarone in NVAF patients.

Twenty-three patients with paroxysmal AF (age 60.9±9.1 years) treated with both drugs concomitantly were included in the study (Table). None of the patients had significant structural heart disease except for 1 with mild left ventricular dysfunction without heart failure. About three quarters of the patients were treated with rivaroxaban 20mg once daily and all were treated with dronedarone 400mg twice daily except for 1 treated with dronedarone 200 twice daily due to bradycardia. Most patients had previously taken other antiarrhythmic agents and switched to dronedarone due to AF recurrence or drug intolerance. A total of 30% of patients switched from vitamin K antagonists to rivaroxaban due to lack of adequate international normalized ratio (INR) control or patient preference and 22% switched from dabigatran to rivaroxaban, when dronedarone was initiated. One patient (4.3%) required dronedarone withdrawal due to drug intolerance. At follow-up (9.1±6.7 months), one quarter of the patients had AF recurrence, and there were no thromboembolic or major bleeding events.


Baseline Characteristics and Clinical Events in Patients With Nonvalvular Atrial Fibrillation Treated With Rivaroxaban and Dronedarone

Number of patients  23 
Age, y  60.9±9.1 
Women, %  52.2 
Creatinine clearance ≥ 50 mL/min, %  91.3 
LVEF>50%, %  95.7 
Paroxysmal atrial fibrillation (%)  100 
Paroxysmal atrial flutter (%)  17.4 
Management of atrial fibrillation
Drug dosage
Rivaroxaban 20mg once daily, %  73.9 
Rivaroxaban 15mg once daily, %  26.2 
Dronedarone 400mg twice daily, %  95.6 
Dronedarone 200mg twice daily, %  4.4 
Time of concomitant treatment with rivaroxaban and dronedarone, mo  9.1±6.7 
Previous use of vitamin K antagonists, %  30.4 
Previous use of dabigatran, %  21.7 
Previous use of antiarrhythmic drugs, %)  73.9 
Clinical events during concomitant treatment with rivaroxaban and dronedarone
Atrial fibrillation recurrence, %  26.1 
Liver enzyme elevation, % 
Thromboembolic events, % 
Major bleeding, % 

LVEF, left ventricular ejection fraction.

Dronedarone is a moderate CYP 3A4 inhibitor, a mild CYP 2D6 inhibitor, and a potent P-gp inhibitor. Rivaroxaban is metabolized via CYP3A4, and is a substrate for the P-gp. Therefore, a potential pharmacodynamic interaction could be expected when both drugs are taken concomitantly.6 However, data on the safety of this combination is currently lacking. To our knowledge, this is the first study of the consequences of combining rivaroxaban with dronedarone.

Our study has some limitations. First, a limited number of patients were included. Second, although most patients had normal renal function, one quarter were taking rivaroxaban 15mg one daily. This could have counterbalanced the effect of the increase in the area under the curve of rivaroxaban. Finally, the follow-up was insufficiently long to establish the efficacy and safety of the combination in the long-term.

In conclusion, our work is the first study that provides evidence that the concomitant administration of both drugs is safe and is not associated with significant adverse events. However, these results need to be validated by further studies.


C. Escobar has received fees for lectures from Bayer, Pfizer, Boehringer Ingelheim, Daiichi Sankyo, and Sanofi. J. L. López-Sendón and J. L. Merino have received fees for consultancy or lectures from Bayer, Pfizer, Boehringer Ingelheim, Daiichi Sankyo, and Sanofi.

C.T. Ruff, R.P. Giugliano, E. Braunwald, et al.
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.
I. Roldán Rabadán, M. Anguita Sánchez, F. Marín, et al.
Current Antiarrhythmic Therapy for Nonvalvular Atrial Fibrillation in Spain. Data From the FANTASIIA Registry.
Rev Esp Cardiol, 69 (2016), pp. 54-60
S.H. Hohnloser, H.J. Crijns, M. van Eickels, et al.
Effect of dronedarone on cardiovascular events in atrial fibrillation.
N Engl J Med, 360 (2009), pp. 668-678
S.H. Hohnloser.
New pharmacological options for patients with atrial fibrillation: the ATHENA trial.
Rev Esp Cardiol, 62 (2009), pp. 479-481
H. Heidbuchel, P. Verhamme, M. Alings, et al.
Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation.
Europace, 17 (2015), pp. 1467-1507
V. Barrios, C. Escobar.
From clinical trials to clinical practice. Experience with rivaroxaban in the anticoagulant treatment of patients with non-valvular atrial fibrillation.
Copyright © 2016. Sociedad Española de Cardiología
Revista Española de Cardiología (English Edition)

Subscribe to our newsletter

Article options
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

es en
Política de cookies Cookies policy
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.